Skip to main content
Oncotarget logoLink to Oncotarget
. 2018 Nov 30;9(94):36720–36721. doi: 10.18632/oncotarget.26431

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Marina Cazzaniga 1,2, Claudio Verusio 3, Mariangela Ciccarese 4, Alberto Fumagalli 5, Donata Sartori 6, Maria Rosaria Valerio 7, Mario Airoldi 8, Gabriella Moretti 9, Corrado Ficorella 10, Valentina Arcangeli 11, Lucrezia Diodati 12, Alberto Zambelli 13, Antonio Febbraro 14, Daniele Generali 15, Mirco Pistelli 16, Ornella Garrone 17, Antonino Musolino 18, Patrizia Vici 19, Michela Maur 20, Lucia Mentuccia 21, Nicla La Verde 22, Giulia Bianchi 23, Salvatore Artale 24, Livio Blasi 25, Michela Piezzo 26, Francesco Atzori 27, Anna Turletti 28, Chiara Benedetto 29, Maria Concetta Cursano 30, Alessandra Fabi 31, Vittorio Gebbia 32, Alessio Schirone 33, Raffaella Palumbo 34, Antonella Ferzi 35, Antonio Frassoldati 36, Claudio Scavelli 37, Luca Clivio 38, Valter Torri, on behalf of The EVA Study Group38
PMCID: PMC6291174  PMID: 30613355

This article has been corrected: The correct author name is given below:

Michela Piezzo

Original article: Oncotarget. 2018; 9:31877-31887. https://doi.org/10.18632/oncotarget.25874


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES